A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms
Philipp Harter,Jalid Sehouli,Domenica Lorusso,Alexander Reuss,Ignace Vergote,Christian Marth,Jae Weon Kim,Francesco Raspagliesi,Björn Lampe,Giovanni Aletti,Werner Meier,David Cibula,Alexander Mustea,Sven Mahner,IB Runnebaum,B Schmalfeldt,Alexander Burges,Rainer Kimmig,Giovanni Scambia,Stefano Greggi,Felix Hilpert,Annette Hasenburg,Peter Hillemanns,Giorgio Giorda,Ingo von Leffern,Carmen Schade-Brittinger,Uwe Wagner,Andreas du Bois +27 more
Reads0
Chats0
TLDR
Systematic pelvic and paraaortic lymphadenectomy in patients with advanced ovarian cancer who had undergone intraabdominal macroscopically complete resection and had normal lymph nodes both before and during surgery was not associated with longer overall or progression‐free survival and was associated with a higher incidence of postoperative complications.Abstract:
Background Systematic pelvic and paraaortic lymphadenectomy has been widely used in the surgical treatment of patients with advanced ovarian cancer, although supporting evidence from rando...read more
Citations
More filters
Journal ArticleDOI
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar,Benjamin O. Anderson,Jame Abraham,Rebecca Aft,Doreen M. Agnese,Kimberly H. Allison,Sarah L. Blair,Harold J. Burstein,Chau T. Dang,Anthony D. Elias,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Jairam Krishnamurthy,Janice A. Lyons,P. Kelly Marcom,Jennifer M. Matro,Ingrid A. Mayer,Meena S. Moran,Joanne E. Mortimer,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Hope S. Rugo,Amy M. Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,Erica Stringer-Reasor,Melinda L. Telli,John H. Ward,Jessica Young,Jennifer L. Burns,Rashmi Kumar +34 more
TL;DR: The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.
Journal ArticleDOI
Treatment of epithelial ovarian cancer
TL;DR: The treatment of recurrent ovarian cancer continues to be nuanced and requires extensive review of up to date modalities that balance efficacy with the patient’s quality of life.
Lymph node involvement in epithelial ovarian cancer: Analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications
Philippe Morice,F. Joulie,Sophie Camatte,David Atallah,Roman Rouzier,Patricia Pautier,Christophe Pomel,Catherine Lhommé,Pierre Duvillard,Damienne Castaigne +9 more
TL;DR: The factors influencing nodal involvement and topography of pelvic and paraaortic node involvement in ovarian carcinoma were determined and lymphadenectomy should be performed even in patients with stage IA disease.
Journal ArticleDOI
Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
TL;DR: New data have emerged that can help guide decision making on the increasingly complex medical and surgical treatment options for women with ovarian cancer.
Journal ArticleDOI
Metastasis-Initiating Cells and Ecosystems
Joan Massagué,Karuna Ganesh +1 more
TL;DR: In this paper, the authors review the nature of metastasis-initiating cells and their ecosystems and offer a perspective on how this knowledge is informing innovative treatments of metastatic cancers.
References
More filters
Journal ArticleDOI
A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J. Perren,Ann Marie Swart,Jacobus Pfisterer,Jonathan A. Ledermann,Eric Pujade-Lauraine,Gunnar B. Kristensen,Mark S. Carey,Philip Beale,Andrés Cervantes,Christian Kurzeder,Andreas du Bois,Jalid Sehouli,Rainer Kimmig,A. Stähle,Fiona Collinson,Sharadah Essapen,Charlie Gourley,Alain Lortholary,Frédéric Selle,Mansoor Raza Mirza,Arto Leminen,Marie Plante,Dan Stark,Wendi Qian,Wendi Qian,Mahesh K. B. Parmar,Amit M. Oza,Icon investigators +27 more
TL;DR: In patients at high risk for progression, the benefit was greater with bevacizumab than without it, with progression-free survival (restricted mean) at 42 months of 14.5 months, higher than the average for women with ovarian cancer.
Journal ArticleDOI
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger,Mark F. Brady,Michael A. Bookman,Gini F. Fleming,Bradley J. Monk,Helen Q. Huang,Robert S. Mannel,Howard D. Homesley,Jeffrey M. Fowler,Benjamin E. Greer,Matthew P. Boente,Michael J. Birrer,Sharon X. Liang +12 more
TL;DR: In this article, a double-blind, placebo-controlled, phase 3 trial was conducted to evaluate the effect of bevacizumab and paclitaxel on progression-free survival in patients with stage III or stage IV epithelial ovarian cancer.
Journal ArticleDOI
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).
Andreas du Bois,Alexander Reuss,Eric Pujade-Lauraine,Philipp Harter,Isabelle Ray-Coquard,Jacobus Pfisterer +5 more
TL;DR: In this paper, an exploratory analysis was conducted of three prospective randomized trials (AGO-OVAR 3, 5, and 7) investigating platinum-taxane based chemotherapy regimens in advanced ovarian cancer conducted between 1995 and 2002.
Journal ArticleDOI
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
Sean Kehoe,Jane Hook,Matthew Nankivell,Gordon C Jayson,Henry C Kitchener,Tito Lopes,David Luesley,Timothy J. Perren,Selina Bannoo,Monica Mascarenhas,Stephen Dobbs,Sharadah Essapen,Jeremy Twigg,Jonathan Herod,Glenn McCluggage,Mahesh K.B. Parmar,Ann Marie Swart,Ann Marie Swart +17 more
TL;DR: In women with stage III or IV ovarian cancer, survival with primary chemotherapy is non-inferior to primary surgery, and giving primary chemotherapy before surgery is an acceptable standard of care for women with advanced ovarian cancer.
Journal ArticleDOI
Incorporation of bevacizumab in the primary treatment of ovarian cancer
Robert A. Burger,Mark F. Brady,Michael A. Bookman,Gini F. Fleming,Bradley J. Monk,Helen Q. Huang,Robert S. Mannel,Howard D. Homesley,Jeffrey M. Fowler,Benjamin E. Greer,Matthew P. Boente,Michael J. Birrer,Sharon X. Liang +12 more
TL;DR: This multinational double-blind placebo-controlled trial was designed to evaluate the addition of bevacizumab to standard front-line ovarian cancer therapy in patients with stage III or IV epithelial ovarian cancer.
Related Papers (5)
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore,Nicoletta Colombo,Giovanni Scambia,Byoung Gie Kim,Ana Oaknin,Michael Friedlander,Alla Lisyanskaya,Anne Floquet,Alexandra Leary,Gabe S. Sonke,Charlie Gourley,Susana Banerjee,Amit M. Oza,Antonio González-Martín,Carol Aghajanian,William H. Bradley,Cara Mathews,Joyce F. Liu,Elizabeth S. Lowe,Ralph Bloomfield,Paul DiSilvestro +20 more